Tanvex BioPharma, Inc. (6541.TW)

TWD 61.4

(-1.6%)

Market Cap (In TWD)

10.07 Billion

Revenue (In TWD)

61.41 Million

Net Income (In TWD)

-2.13 Billion

Avg. Volume

345.36 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
35.05-80.0
PE
-
EPS
-
Beta Value
0.447
ISIN
KYG8676P1037
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Stephen Lam
Employee Count
-
Website
https://www.tanvex.com
Ipo Date
2015-08-13
Details
Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar in Taiwan and the United States. The company focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. Its products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.